About Index Trending news
Analyze
Pricing
Syntimmune

Syntimmune

Work at Syntimmune? Add yourself to this profile

Syntimmune

Founded in 2013, Syntimmune is the worlds leader in the biology of the neonatal Fc receptor (FcRn). Syntimmune's lead program targets FcRn.

Elsewhere

Contributors to this profile

Alexa global traffic share

21 Jun 2017
$50,000,000
Venture capital (Series B)
Partners Innovation Fund, Apple Tree Partners, Baxalta Ventures

Syntimmune Closes $50 Million Series B Financing Led by Apple Tree Partners

businesswire
+2
17 Nov 2016
$8,000,000
Venture capital (Series A)
Partners Innovation Fund, Apple Tree Partners, Baxalta Ventures

Syntimmune Raises $8M Tranche of $26M Series A Funding

FinSMEs
23 Mar 2016
$26,000,000
Venture capital (Series A)
Partners Innovation Fund, Apple Tree Partners, Baxalta Ventures

The Daily Startup: Syntimmune Fights Autoimmune Diseases With New Funds

VentureWire